Sunday 18 October 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNA
Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024. Revenue growth for three consecutive years.
7.67
0.15
−1.92%
Follow RNA
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | (40.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (23.08%) | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (3.40) | |
Free Cash Flow |
— | — | — | (58.08) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | (12.13%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 186.14% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 128.45% | |
Share Based Compensation of Revenue |
— | — | — | 57.08% | |
Operating CF/Net income |
— | — | — | 1.02 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.09 | |
Capex/Depreciation |
— | — | — | 0.00 | |
Revenue per Share |
0.00 | — | 0.00 | 1.64 | |
Operating CF per Share |
0.00 | — | 0.00 | (3.40) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates